Aquilonius S M
Department of Neurology, University of Uppsala, Sweden.
Acta Neurol Scand Suppl. 1991;136:37-9. doi: 10.1111/j.1600-0404.1991.tb05018.x.
From 1983, when dopaminergic structures were visualized for the first time in the human brain by positron emission tomography (PET) and onwards about 120 PET studies on Parkinsons disease have been listed in MEDLINE. With 18F-fluorodopa presynaptic dopamine insufficiency can be demonstrated in PD. By using 11C-nomifensine the dopamine reuptake sites can be visualized with PET. These results indicate that the striatal dopaminergic terminals are relatively preserved in PD as compared to the extreme reductions of dopamine in this region post mortem. Radiolabelled D2-agonists indicate a slight increase in these binding sites in de novo PD and no marked reduction in more advanced disease. 11C-selegiline have been used to demonstrate the intracerebral MAO-B inhibition by therapeutic doses of this drug. 11C-L-dopa and PET have demonstrat the rapid striatal decarboxylation of therapeutic doses of L-dopa also in advanced PD and a rough estimate of the striatal dopamine concentration inducing an "on-response" has been obtained. These contributions of PET to PD research are discussed in the article.
自1983年正电子发射断层扫描（PET）首次在人类大脑中可视化多巴胺能结构以来，MEDLINE上已列出约120项关于帕金森病的PET研究。使用18F-氟多巴可在帕金森病中显示突触前多巴胺不足。通过使用11C-诺米芬辛，可利用PET可视化多巴胺再摄取位点。这些结果表明，与死后该区域多巴胺的极度减少相比，帕金森病患者纹状体多巴胺能终末相对保留。放射性标记的D2激动剂表明，初发帕金森病患者这些结合位点略有增加，而在病情更严重时无明显减少。11C-司来吉兰已被用于证明该药物治疗剂量对脑内MAO-B的抑制作用。11C-L-多巴和PET还证明了在晚期帕金森病中治疗剂量的L-多巴在纹状体的快速脱羧作用，并获得了诱导“开期反应”的纹状体多巴胺浓度的粗略估计。本文讨论了PET对帕金森病研究的这些贡献。
